NRIX

NRIX Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. · NASDAQ
Market Closed
12.85
▼ ⁦-5.51%⁩ (-0.75)
Post-market12.850.00% (0.00)
Market Cap$1.4B
Beta1.82
52w Low52w High
12.0128.23
Last Week
⁦-16.99%⁩
Last Month
⁦-49.63%⁩
Last 3 Months
⁦-51.08%⁩
Last Year
⁦+4.39%⁩
Open on chart
Premium content
Fair Value
Current price⁦$13⁩

    The floor: what the company is worth if growth stopped today

    • Value with no growth
      Today's after-tax operating profit, held flat forever, at a ⁦13.2%⁩ discount rate
      ⁦$28⁩
      ⁦+114%⁩

    10-year US Treasury yield ⁦5.04%⁩ as of ⁦2026-11-19⁩. Estimates computed from company data and analyst targets, not investment advice.

    Premium content

    Get Your Premium Account Now

    • Stock Deep Analysis
    • The Advanced News Platform
    Recommended
    Annual plan
    $700 / yr
    Monthly plan
    $99 / mo
    Premium content
    Which listings have analyst coverage?

    EL7 refreshes analyst ratings and price targets for active company listings on Nasdaq, the New York Stock Exchange and NYSE American, including US-listed depositary receipts. Funds (including ETFs and mutual funds), OTC listings and listings on other exchanges are outside this coverage. Some eligible listings may have no published target or analyst call in the past 12 months.

    EL7 checks for new ratings several times on weekdays, refreshes consensus targets on weekdays and updates monthly rating history once a month.

    Key Financials

    Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

    StockSector medianSector averagetypical sector range
    • P/E (TTM)
      5.56x
      5.82x46.58x
      Very cheap
    • Forward P/E
      —
      —
    • EV / EBITDA
      1.24x
      3.71x29.64x
      Very cheap
    • FCF Yield
      26.4%
      -99.3%7.8%
      Exceptional
    • Revenue Growth YoY
      738.8%
      -48.8%73.2%
      Exceptional
    • EPS Growth YoY
      177.8%
      -103.1%98.8%
      Exceptional
    • Gross Margin
      —
      —
    • ROIC
      37.8%
      -150.5%16.1%
      Exceptional
    • Net Debt / EBITDA
      -3.47x
      0.00x1.99x
      Net cash
    • Dividend Yield
      Pays no dividend
      —
    • Payout Ratio
      Pays no dividend
      —
    • Altman Z-Score
      5.33
      -17.7515.77
      Above average
    Financial Analysis
    Related News

    Frequently Asked Questions

    What is Nurix Therapeutics, Inc. stock?▼

    Nurix Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

    How can I invest in Nurix Therapeutics, Inc.?▼

    You can buy Nurix Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.

    What are the key metrics for evaluating Nurix Therapeutics, Inc.?▼

    Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

    Does Nurix Therapeutics, Inc. pay dividends?▼

    Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

    What are the risks of investing in Nurix Therapeutics, Inc.?▼

    Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.